As the leading Duchenne muscular dystrophy (DMD) charity in the UK, we aim to end Duchenne's devastating impact. We connect scientists, the pharmaceutical industry, the NHS and families to advance and accelerate medical research, while bringing everyone affected by DMD the care and support they need.
We need to go further than anyone has before to find effective treatments. This means setting our ambitions high and overcoming every barrier in our way.
We’re going to do it faster, because this generation of people living with DMD can’t wait.
The only way we can achieve this is together. We create a network of mutual support for families. We collaborate with scientists and the pharmaceutical industry, bringing them together to share knowledge. And we work with health services so that patients get the care they need.
Join our next Parent Information Day on 1 October 2022 in London to learn about the latest care guidance, research, and connect with other DMD parents and caregivers
Find out more
Join our mission to fund life-changing DMD treatments by fundraising, donating, or joining an event.
Get involved
Duchenne UK is collaborating on an initiative to improve DMD care throughout the UK by providing clinical recommendations.
Visit the DMD Care UK website
The DMD Hub is a network of sites carrying out clinical studies for Duchenne muscular dystrophy.
Visit the DMD Hub site
By funding staff posts at the Royal Hospital for Children, Glasgow, the DMD Hub has enabled more trials to take place and more boys in Scotland to take part in research
Read More
Dedicated specialist support for Duchenne muscular dystrophy (DMD) patients and families’ mental health and wellbeing will soon be more readily available, as part of the DMD Care UK project.
Read More
NICE and NHS England have released a statement about continued access for DMD patients currently being treated with ataluren
Read More
A group of experts have concluded an analysis on data from the trial of tamoxifen in boys with DMD.
Read More
We aim to share the most important news in drug development with the DMD community through our quarterly roundup.
Read More
CEO Emily Reuben spoke at the ABPI conference and shared this thought piece on access to DMD treatments
Read More
LCH have continued their sponsorship for the 10th Duchenne Dash. Hear from a first-time rider about their experience cycling from London to Paris!
Read More
A new drug aiming to slow progression of DMD, Givinostat, has shown positive results in a clinical trial.
Read More
Our CEO Emily Reuben shares her personal story as Krishnan Guru-Murthy presents the Radio 4 Appeal for Duchenne UK today
Read More
Sign up for the latest news on DMD research, upcoming events and ways to get involved.
